Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA.
Cancer Biol Ther. 2020 May 3;21(5):441-451. doi: 10.1080/15384047.2020.1721262. Epub 2020 Feb 9.
Sporadic colorectal cancer initiates with mutations in APC or its degradation target β-catenin, producing TCF-dependent nuclear transcription driving tumorigenesis. The intestinal epithelial receptor, GUCY2C, with its canonical paracrine hormone guanylin, regulates homeostatic signaling along the crypt-surface axis opposing tumorigenesis. Here, we reveal that expression of the guanylin hormone, but not the GUCY2C receptor, is lost at the earliest stages of transformation in APC-dependent tumors in humans and mice. Hormone loss, which silences GUCY2C signaling, reflects transcriptional repression mediated by mutant APC-β-catenin-TCF programs in the nucleus. These studies support a pathophysiological model of intestinal tumorigenesis in which mutant APC-β-catenin-TCF transcriptional regulation eliminates guanylin expression at tumor initiation, silencing GUCY2C signaling which, in turn, dysregulates intestinal homeostatic mechanisms contributing to tumor progression. They expand the mechanistic paradigm for colorectal cancer from a disease of irreversible mutations in APC and β-catenin to one of guanylin hormone loss whose replacement, and reconstitution of GUCY2C signaling, could prevent tumorigenesis.
散发性结直肠癌的发生起始于 APC 或其降解靶标β-连环蛋白的突变,产生依赖 TCF 的核转录驱动肿瘤发生。肠上皮细胞受体 GUCY2C 及其经典旁分泌激素鸟苷酸环化酶 C(guanylin),沿隐窝-表面轴调节与肿瘤发生相反的稳态信号。在这里,我们揭示了在人类和小鼠中 APC 依赖性肿瘤的最早转化阶段,失去了鸟苷酸环化酶 C 激素而不是 GUCY2C 受体的表达。这种激素丢失,沉默了 GUCY2C 信号,反映了核中转录因子 APC-β-连环蛋白-TCF 程序介导的转录抑制。这些研究支持了一种肠道肿瘤发生的病理生理学模型,其中突变型 APC-β-连环蛋白-TCF 转录调控在肿瘤起始时消除了鸟苷酸环化酶 C 的表达,沉默了 GUCY2C 信号,进而使肠道稳态机制失调,促进肿瘤进展。它们将结直肠癌的机制范例从 APC 和 β-连环蛋白不可逆突变的疾病扩展为鸟苷酸环化酶 C 激素丢失的疾病,其替代和 GUCY2C 信号的重建可能预防肿瘤发生。